- Tight genes
"There's no room at the inn." That's the message emerging biotechnology companies have been hearing when they apply for incubator space on Long Island. The result: the Maryland Bioscience Alliance and equivalent groups in Massachusetts, Connecticut and New Jersey - home of Big Pharma companies - are attempting to lure ......
- New York City gets serious about
biotech.
As Martha Stewart's insider trading trial drags on, avid gossipers tend to forget the whole mess sprouted from a controversy involving the biotech industry--an industry that is thriving in New York. The approval by the Food and Drug Administration last week of the cancer drug Erbitux--whose initial pending rejection led ......
- Biosciences scorecard: report finds Indiana one of the country's top three life-sciences states.
WHEN EVALUATING Indiana's life-sciences status, it might be useful to employ former New York City mayor Ed Koch's daily refrain, 'How'm I doing?" It was daily because he knew he needed to keep his finger on the pulse--things can change in a heartbeat. And with all 50 states and many ......
- Orthovita, Inc. Appoints New Director.
Paul Touhey of Fujirebio Diagnostics, Inc. joins Orthovita's Board of Directors MALVERN, Pa. -- Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, announced the appointment of Paul Touhey to its Board of Directors (the "Board") today. Mr. Touhey has over twenty-five years of experience in the healthcare, medical device, ......
- Metabolix Names New Member to the Board of Directors.
CAMBRIDGE, Mass. -- Metabolix Inc. (NASDAQ:MBLX), a bioscience company developing and commercializing environmentally sustainable and totally biodegradable Natural Plastic, announced today that the company has named Peter N. Kellogg to its Board of Directors, effective March 30, 2007. Mr. Kellogg is Executive Vice President, Finance and Chief Financial Officer of ......
- NYC biotech plan raises Island hopes
With a $700 million, 872,000-square-foot biotech incubator possibly breaking ground in New York City before 2007, local bioscience experts are thinking big.
- Have stem cells finally arrived? Despite fraud and
controversy, signs point to an emerging, money-making
industry.
Before the end of 2006, a Silicon Valley biotech company called Geron hopes to start human trials of a new treatment to replace the missing insulation around nerve fibers that plays a crucial role in spinal cord injuries and multiple sclerosis. To do this, Geron would inject into patients' spinal ......